| [1] |
Paczosa MK, Mecsas J. Klebsiella pneumoniae: going on the offense with a strong defense[J]. Microbiol Mol Biol Rev,2016,80(3):629-661.
|
| [2] |
杭文璐, 杜永亮, 李占结, 等. 免疫功能缺陷患者碳青霉烯类耐药肺炎克雷伯菌院内感染一例[J/CD]. 中华实验和临床感染病杂志(电子版),2022,16(3):205-209.
|
| [3] |
Li S, Yu S, Peng M, et al. Clinical features and development of Sepsis in Klebsiella pneumoniae infected liver abscess patients: a retrospective analysis of 135 cases[J]. BMC Infect Dis,2021,21(1):597.
|
| [4] |
Shields RK, Zhou Y, Kanakamedala H, et al. Burden of illness in US hospitals due to carbapenem-resistant Gram-negative urinary tract infections in patients with or without bacteraemia[J]. BMC Infect Dis,2021,21(1):572.
|
| [5] |
Wu X, Shi Q, Shen S, et al. Clinical and bacterial characteristics of Klebsiella pneumoniae affecting 30-day mortality in patients with bloodstream infection[J]. Front Cell Infect Microbiol,2021,11:688989.
|
| [6] |
Luan Y, Sun Y, Duan S, et al. Pathogenic bacterial profile and drug resistance analysis of community-acquired pneumonia in older outpatients with fever[J]. J Int Med Res,2018,46(11):4596-4604.
|
| [7] |
Venkataraman R, Divatia JV, Ramakrishnan N, et al. Multicenter observational study to evaluate epidemiology and resistance patterns of common intensive care unit-infections[J]. Indian J Crit Care Med,2018,22(1):20-26.
|
| [8] |
Zhu J, Wang T, Chen L, et al. Virulence factors in hypervirulent Klebsiella pneumoniae[J]. Front Microbiol,2021,12:642484.
|
| [9] |
Coates M, Blanchard S, MacLeod AS. Innate antimicrobial immunity in the skin: a protective barrier against bacteria, viruses, and fungi[J]. PLoS Pathog,2018,14(12):e1007353.
|
| [10] |
Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine[J]. Nat Rev Drug Discov,2007,6(12):975-990.
|
| [11] |
Liu T, Zhang L, Joo D, et al. NF-κB signaling in inflammation[J]. Sig Transduct Target Ther,2017,2(1):17023.
|
| [12] |
McNab F, Mayer-Barber K, Sher A, et al. Type Ⅰ interferons in infectious disease[J]. Nat Rev Immunol,2015,15(2):87-103.
|
| [13] |
Philips RL, Wang Y, Cheon H, et al. The JAK-STAT pathway at 30: much learned, much more to do[J]. Cell,2022,185(21):3857-3876.
|
| [14] |
Tam JCH, Jacques DA. Intracellular immunity: finding the enemy within--how cells recognize and respond to intracellular pathogens[J]. J Leukoc Biol,2014,96(2):233-244.
|
| [15] |
Ablasser A, Hur S. Regulation of cGAS- and RLR-mediated immunity to nucleic acids[J]. Nat Immunol,2020,21(1):17-29.
|
| [16] |
Ji L, Li T, Chen H, et al. The crucial regulatory role of type Ⅰ interferon in inflammatory diseases[J]. Nat Rev Immunol,2023,13(1):230.
|
| [17] |
Shemesh M, Lochte S, Piehler J, et al. IFNAR1 and IFNAR2 play distinct roles in initiating type Ⅰ interferon-induced JAK-STAT signaling and activating STATs[J]. Sci Signal,2021,14(710):eabe4627.
|
| [18] |
Stanifer ML, Pervolaraki K, Boulant S. Differential regulation of type Ⅰ and type Ⅲ interferon signaling[J]. Int J Mol Sci,2019,20(6):E1445.
|
| [19] |
Platanias LC. Mechanisms of type-Ⅰ- and type-Ⅱ-interferon-mediated signalling[J]. Nat Rev Immunol,2005,5(5):375-386.
|
| [20] |
Yang E, Li MMH. All about the RNA: interferon-stimulated genes that interfere with viral RNA processes[J]. Front Immunol, 2020,11:605024.
|
| [21] |
Mazewski C, Perez RE, Fish EN, et al. Type Ⅰ interferon (IFN)-regulated activation of canonical and non-canonical signaling pathways[J]. Front Immunol,2020,11:606456.
|
| [22] |
Bourdon M, Manet C, Montagutelli X. Host genetic susceptibility to viral infections: the role of type Ⅰ interferon induction[J]. Genes Immun,2020,21(6):365-379.
|
| [23] |
Zeng C, Waheed AA, Li T, et al. SERINC proteins potentiate antiviral type Ⅰ IFN production and proinflammatory signaling pathways[J]. Sci Signal,2021,14(700):eabc7611.
|
| [24] |
Ivin M, Dumigan A, de Vasconcelos FN, et al. Natural killer cell-intrinsic type Ⅰ IFN signaling controls Klebsiella pneumoniae growth during lung infection[J]. PLoS Pathog,2017,13(11):e1006696.
|
| [25] |
Doran CG, Sugisawa R, Carty M, et al. CRISPR/Cas9-mediated SARM1 knockout and epitope-tagged mice reveal that SARM1 does not regulate nuclear transcription, but is expressed in macrophages[J]. J Biol Chem,2021,297(6):101417.
|
| [26] |
Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledge-based Human Protein Atlas[J]. Nat Biotechnol,2010,28(12):1248- 1250.
|
| [27] |
Feriotti C, Sá-Pessoa J, Calderón-González R, et al. Klebsiella pneumoniae hijacks the Toll-IL-1R protein SARM1 in a type Ⅰ IFN-dependent manner to antagonize host immunity[J]. Cell Rep,2022,40(6):111167.
|
| [28] |
Frank CG, Reguerio V, Rother M, et al. Klebsiella pneumoniae targets an EGF receptor-dependent pathway to subvert inflammation[J]. Cell Microbiol,2013,15(7):1212-1233.
|
| [29] |
Cao W, Li J, Yang K, et al. An overview of autophagy: mechanism, regulation and research progress[J]. Bull Cancer,2021,108(3):304-322.
|
| [30] |
刘会雪, 张佩佩, 安江科. 三七皂甙R1调节蛋白酪氨酸激酶2/信号转导与转录激活因子3信号通路对肺炎克雷伯菌感染的肺泡上皮细胞损伤的影响[J]. 中国热带医学,2023,23(7):754-760.
|
| [31] |
Yanai H, Taniguchi T. Fine-tuning type Ⅰ IFN signaling: a new chapter in the IFN saga[J]. Cell Res,2017,27(12):1407-1408.
|
| [32] |
Divangahi M, King IL, Pernet E. Alveolar macrophages and type I IFN in airway homeostasis and immunity[J]. Trends Immunol,2015,36(5):307-314.
|
| [33] |
Trevejo-Nuñez G, Lin B, Fan L, et al. Regnase-1 deficiency restrains Klebsiella pneumoniae infection by regulation of a type Ⅰ interferon response[J]. mBio,2021,13(1):e0379221.
|
| [34] |
López-Rodríguez JC, Hancock SJ, Li K, et al. Type Ⅰ interferons drive MAIT cell functions against bacterial pneumonia[J]. J Exp Med,2023,220(10):e20230037.
|